Our flagship project, GRAM, seeks to estimate the burden of antimicrobial resistance worldwide using data, health statistics and geospatial maps. The team are adapting and refining methodologies established in IHME’s ongoing GBD study to build an evidence base of antibiotic resistance across the globe, with corresponding maps. Our initial focus are the following 17 pathogen-antibacterial combinations. We will examine the resistance burden estimates for these combinations from 1990 to the present time in all 195 countries included in IHME’s GBD Study. The findings will assist the global research community and policymakers in tailoring interventions at the international, national and local level. The results will be freely available as interactive data visualisations on the IHME website.
|Escherichia coli||Third-generation cephalosporins, fluoroquinolones|
|Klebsiella pneumoniae||Third-generation cephalosporins, carbapenems|
|Salmonella Typhi and Paratyphi||Fluoroquinolones, chloramphenicol|
|Neisseria gonorrhoeae||Third-generation cephalosporins|
First-line - isoniazid, rifampicin
Second-line - fluoroquinolones, amikacin, capreomycin, kanamycin